Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2023European Heart Journal SupplementsOpen Access

Gliflozins and incretins have been demonstrated to slow down the slope of eGFR reduction and significantly impact cardiovascular prognosis by reducing the incidence of clinical events in patients with CKD, irrespective of diabetic status.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Traditional CKD management based on risk-factor control and renin-angiotensin-aldosterone system inhibitors proved only partially effective at preventing renal decline and associated cardiovascular events.

Population

Patients with chronic kidney disease (CKD)

Design

Review

Authors

GCGennaro CiceLMLuca MonzoLCLeonardo Calò

Discussion

Loading...

Member takes

Overview

Preserving eGFR may reduce CV events in CKD now; leaves open broader use of gliflozins beyond current indications.

Structured PICO

P
Population
Patients with chronic kidney disease (CKD)
I
Intervention
Gliflozins and incretins
O
Outcome
Cardiovascular events (fatal and non-fatal heart attack, stroke, heart failure, mortality) and progressive reduction in eGFR

Gliflozins and incretins offer a cardio-nephro-metabolic approach to slowing CKD progression and reducing cardiovascular risk, irrespective of diabetic status.

Cite This Study

Cice et al. (2023) studied this question.

synapsesocial.com/papers/6a7fbc8406444dc1a69febbehttps://doi.org/10.1093/eurheartjsupp/suad067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Can we slow down the decline in renal function?2024 · 1 citations
  2. 2Therapeutic Considerations in Preventing Chronic Kidney Disease2025
  3. 3Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines2024 · 15 citations
  4. 4A study to assess the associated risk of developing cardiovascular diseases in chronic kidney disease2024 · 4 citations
  5. 5Novel drugs and intervention strategies for the treatment of chronic kidney disease2013 · 44 citations